11/02/2026
𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗼𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗱𝗶𝗱𝗻’𝘁 𝘀𝘁𝗮𝗿𝘁 𝗮𝘀 𝗮𝗻 𝗲𝗮𝗿𝗹𝘆-𝗰𝗮𝗿𝗲 𝘁𝗼𝗼𝗹, 𝗯𝘂𝘁 𝗶𝘁’𝘀 𝗯𝗲𝗰𝗼𝗺𝗶𝗻𝗴 𝗼𝗻𝗲.
Precision oncology is still widely viewed as a last-resort tool, something reserved for when standard options have failed.
That perception shapes when testing is ordered, how results are prioritized, and whether molecular data is allowed to influence early clinical decisions.
𝗧𝗵𝗶𝘀 𝗶𝘀 𝗻𝗼𝘁 𝘁𝗵𝗲 𝗰𝗮𝘀𝗲 𝗮𝗻𝘆𝗺𝗼𝗿𝗲.
While precision oncology proved its value in advanced and metastatic disease, it is increasingly being applied earlier in care. Molecular profiling at diagnosis can help guide first-line therapy, support more targeted treatment selection, and avoid approaches that add toxicity without benefit.
The timing matters, the same molecular insight can be clinically transformative when introduced upfront, but far less impactful if it enters the workflow only after resistance and clonal evolution have already taken hold.
These approaches extend beyond treatment selection alone. Early molecular insights can inform risk stratification, support decisions around adjuvant therapy, and increasingly guide monitoring strategies such as tumor-informed residual disease assessment.
This shifts precision oncology from a reactive tool to a proactive framework across the cancer journey.
Using precision approaches earlier can reduce trial-and-error treatment paths, support more informed sequencing decisions, and better align care with tumor biology from the start rather than as a corrective step later.
Precision oncology is not just for when options run out, it's becoming part of how cancer is understood and treated from the beginning.
If you’re early in exploring when and how precision oncology fits into care, our team has developed a straightforward playbook to support that learning. ↓
